Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC
The purpose of this study is to test how a new immunotherapy drug called pembrolizumab affects cancer cells through measuring prostate specific antigen (PSA), imaging studies, and tissue and blood samples. The research will involve molecular, cellular, and immunologic (immune system) experiments that use blood and tumor specimens. Investigators hope that the information gained from these studies will lead to a greater understanding of immune therapy for prostate cancer and potentially, improvements in prostate cancer treatment.
Metastatic Castrate Resistant Prostate Cancer
-Prostate cancer that has spread outside the prostate and no longer responds to hormone therapy
-current use of enzalutamide, with cancer progressing despite this treatment
-no prior immunotherapy
18 - 99
Healthy Volunteers Needed
Duration of Participation
12 weeks to 48 weeks
OHSU Knight Cancer Institute Information Line
OHSU Knight Cancer Institute, supported by Merck Sharp & Dohme Corp.